Gado via Getty Images, FILEthe safety and efficacy of the combo vaccine compared to flu and COVID vaccines that are administered separately in two groups, one involving 4,000 adults aged 65 and older and another involving 4,000 adults between ages 50 and 64., data showed that the vaccine candidate achieved antibody levels similar or greater to the licensed standalone influenza vaccine and to Moderna's COVID vaccine.
The company previously announced that it is aiming for regulatory approval for the combination vaccine in 2025."Flu and COVID-19 represent a significant seasonal burden for individuals, providers, healthcare systems and economies," Moderna CEO Stéphane Bancel said earlier this month in a statement when phase I/II clinical trial data was released.